Wendel Garcia, Pedro David http://orcid.org/0000-0001-7775-3279
Hilty, Matthias Peter http://orcid.org/0000-0002-2765-881X
Held, Ulrike http://orcid.org/0000-0003-3105-5840
Kleinert, Eva-Maria
Maggiorini, Marco http://orcid.org/0000-0001-8180-2117
Funding for this research was provided by:
cystosorbents europe gmbh
Article History
Received: 11 June 2021
Accepted: 17 August 2021
First Online: 1 September 2021
Declarations
:
: MM reported receiving research grants from CytoSorbents Europe GmbH (Berlin, Germany) and Baxter International Inc. (Deerfield, USA), as well as personal fees for his work as external consultant from Baxter International Inc. (Deerfield, USA) and Toray Industries Inc. (Tokyo, Japan). All other authors declare no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and Swiss national research committee, with the 1964 Helsinki Declaration and its later amendments and with the guidelines on Good Clinical Practice issued by the European Medicines Agency. The study was approved by the cantonal ethics committee of Zurich (BASEC: ZH 201800559).
: Written informed consent for participation from the patient or in case of death or disability, from the next of kin or legal representative, was sought for every patient prospectively treated with the cytokine adsorber. In the historical cohort, a retrospective informed consent collection process was followed.
: Written informed consent for publication from the patient or, in case of death or disability, from the next of kin or legal representative was sought for every patient prospectively treated with the cytokine adsorber. In the historical cohort, a retrospective informed consent collection process was followed.
Free to read: This content has been made available to all.